Evaluating the Episodic Future Thinking Intervention for Reducing Cigarette Consumption in Cigarette Smokers

Cigarette Smoking-Related Carcinoma Clinical Trial

Official title:

Pilot Study of Episodic Future Thinking Among Cigarette Smokers

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05825001
• Other study ID #: I 2684022
• Status: Recruiting
• Phase: N/A
• Start date: June 30, 2024
• Est. completion date: February 22, 2025

Study information

• Verified date: May 2024
• Source: Roswell Park Cancer Institute
• Contact: Christine Sheffer
• Phone: 716-845-1186
• Email: Christine.Sheffer[@]roswellpark.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This clinical trial evaluates the effectiveness of active episodic future thinking (EFT) stimuli for reducing cigarette consumption in cigarette smokers. EFT is an innovative framing method shown to significantly activate brain regions involved in future thinking, planning, and other executive functions. Active EFT stimuli are positive events, unrelated to smoking, that participants anticipate, look forward to, and can vividly imagine happening up to 1 year in the future. Control EFT stimuli are positive past events, unrelated to smoking, that participants can vividly remember happening in the recent past. Active EFT stimuli may help reduce cigarette consumption among cigarette smokers by exposing them to personally relevant future oriented stimuli.

Description:

PRIMARY OBJEECTIVE:

I. To evaluate the efficacy of episodic future thinking (EFT) for smoking cessation.

OUTLINE: Participants are randomized to 1 of 2 arms.

ARM I (ACTIVE): Participants receive the active EFT stimulus and use the iCOquit Smokerlyzer carbon monoxide monitor on study.

ARM II (CONTROL): Participants receive the control EFT stimulus and use the iCOquit Smokerlyzer carbon monoxide monitor on study.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 96
• Est. completion date: February 22, 2025
• Est. primary completion date: February 22, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Smoke >= 10 cigarettes daily

• > 32 on the Vividness of Visual Imagery Questionnaire (VVIQ)

• No regular use of other tobacco products

• In possession of a smartphone with text messaging capabilities

• Willing to quit smoking in the next 30 days

• Low socioeconomic status

Exclusion Criteria:

• Unable or unwilling to provide verbal consent

• Unable or unwilling to provide data to the research team

• Current use of nicotine replacement therapy, bupropion, or varenicline

• Use of drugs of abuse in the past 30 days

• Living in the same household as a participant already enrolled in this study

Related Conditions & MeSH terms

• Cigarette Smoking-Related Carcinoma

Intervention

Behavioral:
• Smoking Cessation Intervention
Receive active EFT stimulus
• Smoking Cessation Intervention (control)
Receive control EFT stimulus

Other:
• Medical Device Usage and Evaluation
Use iCOquit Smokerlyzer carbon monoxide monitor

Locations

Country	Name	City	State
United States	Roswell Park Comprehensive Cancer Center	Buffalo	New York

Sponsors (1)

Lead Sponsor	Collaborator
Roswell Park Cancer Institute

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Concentration of carbon monoxide on breath	Will be measured by ICOquit Smokerlyzer	From baseline up to 30 days
Secondary	Reduction in delay discounting rate	participants will be guided to imagine the situational and sensory details for each of the stimuli until the vividness scores are = 4 on a scale of 1-5 (1=very low, 5=very high).	Up to 30 days